- Home
- OPRX vs LRMR Comparison
OPRX vs LRMR Comparison
Compare OPRX & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OPRX | LRMR |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | N/A | 65 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 222.6M | 280.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | OPRX | LRMR |
|---|---|---|
| Price | $10.82 | $3.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $19.67 | $16.50 |
| AVG Volume (30 Days) | 300.9K | ★ 1.3M |
| Earning Date | 03-05-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $109,506,000.00 | N/A |
| Revenue This Year | $19.77 | N/A |
| Revenue Next Year | $11.33 | N/A |
| P/E Ratio | $5,970.49 | ★ N/A |
| Revenue Growth | ★ 24.18 | N/A |
| 52 Week Low | $3.99 | $1.61 |
| 52 Week High | $22.25 | $5.37 |
Technical Indicators
Market Signals| Indicator | OPRX | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 39.09 | 37.36 |
| Support Level | $9.73 | $3.06 |
| Resistance Level | $11.91 | $3.61 |
| Average True Range (ATR) | 0.79 | 0.21 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 41.38 | 8.45 |
Price Performance
Historical ComparisonAbout OPRX OptimizeRx Corporation
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its product offerings are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.